Related Experiment Videos
Hypertension and hyperlipidemia. A review
1Department of Geriatrics, Uppsala University, Sweden.
American Journal of Hypertension
|November 1, 1993
Summary
Antihypertensive treatments show less coronary artery disease risk reduction than expected, but stroke reduction is consistent. Some blood pressure medications worsen metabolic issues like insulin resistance and lipid abnormalities, increasing cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Metabolic Syndrome
- Pharmacology
Background:
- Hypertension is linked to metabolic differences, including insulin resistance and lipid abnormalities.
- Observational studies suggest expected risk reductions for coronary artery disease (CAD) and stroke with blood pressure management.
- Antihypertensive and lipid-lowering treatments have demonstrated varying degrees of risk reduction.
Purpose of the Study:
- To evaluate the effectiveness of antihypertensive treatments on coronary artery disease (CAD) risk reduction compared to observational data.
- To assess the impact of antihypertensive medications on the metabolic profiles of hypertensive patients.
- To highlight the importance of considering metabolic effects of drugs in hypertension management.
Main Methods:
- Meta-analysis of 13 antihypertensive treatment studies.
- Meta-analysis of 22 lipid-lowering studies.
- Review of cross-sectional studies on metabolic differences in hypertensive individuals.
Main Results:
- Antihypertensive treatment showed a 14% CAD risk reduction, lower than the 20-25% expected from observational studies for a 5-6 mm Hg diastolic blood pressure reduction.
- Stroke risk reduction was consistent with expectations for the achieved blood pressure reduction.
- Lipid-lowering studies showed CAD risk reduction consistent with epidemiologic observations (20-30% risk difference for 10% cholesterol difference).
- Hypertensive individuals exhibit metabolic differences, including insulin resistance and lipid abnormalities.
- Certain antihypertensive drugs, like beta-blockers, can worsen insulin resistance, lipid profiles, and lipoprotein oxidation, potentially increasing atherogenicity.
Conclusions:
- The observed CAD risk reduction from antihypertensive treatment is less than anticipated based on observational data.
- Metabolic disturbances in hypertensive patients are significant and drug-induced metabolic effects require careful consideration during treatment.
- Tailoring antihypertensive therapy to individual metabolic profiles and drug-specific metabolic effects is crucial for optimal patient outcomes.